{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:06:37Z","timestamp":1784646397415,"version":"3.55.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Haemophilia A is an X-linked bleeding disorder resulting from factor VIII deficiency. While surgical management requires the correction of factor VIII levels by the administration of factor VIII concentrate, antiplatelet therapy after lower-risk cardiac surgery\/procedures (such as transcatheter aortic valve implantation\u2014TAVI) is not yet standardized. This report describes the management of a patient with moderate haemophilia A undergoing TAVI for severe aortic stenosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 76-year-old man with untreated haemophilia A was admitted with traumatic bleeding. After initial stabilization, he developed acute heart failure due to newly discovered severe aortic stenosis. TAVI procedure was performed by transfemoral access according to multidisciplinary team-discussion; a bio-prosthetic valve was successfully implanted. We outline the peri-procedural haemostatic management, which included factor VIII replacement therapy to achieve guideline-recommended activity levels, followed by progressive dose reduction. In view of the high bleeding risk and absence of significant coronary artery disease, antiplatelet therapy was limited to a short course. The procedure was successful, with no bleeding complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In our patient, replacement therapy with rFVIII was initiated with a target FVIII activity between 80 and 100 IU\/dL. During the procedure, unfractionated heparin was administered to achieve an ACT target 29 of 200 s. Post-operatively, FVIII replacement therapy was maintained above 60 IU\/dL for the first 30-72 h, followed by 40-50 IU\/dL from day 4 to day 7. Subsequently, it was decided to continue low-dose FVIII replacement for 32 additional 7 days. This strategy led to a successful management of both cardiological and hematological aspects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although evidence is limited to case reports, TAVI appears to be feasible and safe in patients with haemophilia A. Maintaining high factor VIII activity levels and minimizing antithrombotic exposure through multidisciplinary evaluation can effectively reduce haemorrhagic risk. Our case, in line with previous reports, resulted in no bleeding complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytag484","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:55:20Z","timestamp":1783598120000},"source":"Crossref","is-referenced-by-count":0,"title":["A case report of the coagulation management of an adult with moderate haemophilia A undergoing transcatheter aortic valve implantation"],"prefix":"10.1093","volume":"10","author":[{"given":"Vincent Roger","family":"Gianolli","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ospedale San Giovanni , via Gallino 12, 6500 Bellinzona ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3671-7227","authenticated-orcid":false,"given":"Erica","family":"Terazzi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ospedale San Giovanni , via Gallino 12, 6500 Bellinzona ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Trotti","sequence":"additional","affiliation":[{"name":"Department of Haematology, Istituto Oncologico Della Svizzera Italiana (IOSI), Ospedale San Giovanni , via Gallino 12, 6500 Bellinzona ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Biguzzi","sequence":"additional","affiliation":[{"name":"Department of Haematology, Istituto Oncologico Della Svizzera Italiana (IOSI), Ospedale San Giovanni , via Gallino 12, 6500 Bellinzona ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Di Simone","sequence":"additional","affiliation":[{"name":"Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale , via Tesserete 48, 6900 Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Menafoglio","sequence":"additional","affiliation":[{"name":"Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale , via Tesserete 48, 6900 Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Demarchi","sequence":"additional","affiliation":[{"name":"Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale , via Tesserete 48, 6900 Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"2026072110563392200_ytag484-B1","volume-title":"StatPearls","author":"Salen","year":"2026"},{"key":"2026072110563392200_ytag484-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of Hemophilia, 3rd edition","volume":"26 Suppl 6","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"2026072110563392200_ytag484-B3","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Hemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"2026072110563392200_ytag484-B4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026072110563392200_ytag484-B5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2026072110563392200_ytag484-B6","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(19)30042-X","article-title":"The MATRIX trial","volume":"393","author":"Shah","year":"2019","journal-title":"Lancet"},{"key":"2026072110563392200_ytag484-B7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12471-021-01638-8","article-title":"Major threats to early safety after transcatheter aortic valve implantation in a contemporary cohort of real-world patients","volume":"29","author":"Van Ginkel","year":"2021","journal-title":"Neth Heart J"},{"key":"2026072110563392200_ytag484-B8","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.hrthm.2020.05.040","article-title":"Long-term percentage of ventricular pacing in patients requiring pacemaker implantation after transcatheter aortic valve replacement: a multicenter 10-year experience","volume":"17","author":"Baldi","year":"2020","journal-title":"Heart Rhythm"},{"key":"2026072110563392200_ytag484-B9","article-title":"Prevention and treatment strategies for pocket hematomas during CIED implantation: pocket management systems and other adjuvant interventions","author":"Kanuri","year":"2020","journal-title":"Heart Rhythm Case Rep"},{"key":"2026072110563392200_ytag484-B10","doi-asserted-by":"crossref","DOI":"10.3390\/life14030354","article-title":"Modern treatment of valvulopathies in patients with congenital Hemophilia","volume":"14","author":"Badescu","year":"2024","journal-title":"Life"},{"key":"2026072110563392200_ytag484-B11","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000900","article-title":"Antithrombotic treatment in patients with hemophilia: an EHA\u2013ISTH\u2013EAHAD\u2013ESO clinical practice guidance","volume":"7","author":"Schutgens","year":"2023","journal-title":"HemaSphere"},{"key":"2026072110563392200_ytag484-B12","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1111\/hae.12693","article-title":"Transcatheter aortic valve implantation in a person with Hemophilia","volume":"21","author":"Merron","year":"2015","journal-title":"Haemophilia"},{"key":"2026072110563392200_ytag484-B13","doi-asserted-by":"crossref","first-page":"e500","DOI":"10.1111\/hae.12771","article-title":"Percutaneous transluminal aortic valve implantation for severe aortic valve stenosis in a patient with severe Hemophilia A","volume":"21","author":"Giuffrida","year":"2015","journal-title":"Haemophilia"},{"key":"2026072110563392200_ytag484-B14","author":"L\u00f3pez"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytag484\/68742398\/ytag484.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/7\/ytag484\/68742398\/ytag484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/7\/ytag484\/68742398\/ytag484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:56:41Z","timestamp":1784645801000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytag484\/8729600"}},"subtitle":[],"editor":[{"given":"Rita","family":"Pavasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Luis Antonio","family":"Moreno-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Matteo","family":"Arzenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytag484","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"ytag484"}}